As of 2026-10-03, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -24.91. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 2,130.96 mil USD. URGN's TTM EBITDA according to its financial statements is -85.54 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 8.0x | 6.6x |
| Forward P/E multiples | 5.7x - 8.5x | 7.1x |
| Fair Price | (12.31) - (16.35) | (14.41) |
| Upside | -129.7% - -139.5% | -134.8% |
| Date | EV/EBITDA |
| 2026-09-30 | -24.47 |
| 2026-09-29 | -24.37 |
| 2026-09-28 | -24.63 |
| 2026-09-25 | -24.88 |
| 2026-09-24 | -24.81 |
| 2026-09-23 | -25.04 |
| 2026-09-22 | -25.69 |
| 2026-09-21 | -25.94 |
| 2026-09-18 | -25.96 |
| 2026-09-17 | -26.36 |
| 2026-09-16 | -26.10 |
| 2026-09-15 | -25.10 |
| 2026-09-14 | -25.62 |
| 2026-09-11 | -25.43 |
| 2026-09-10 | -25.39 |
| 2026-09-09 | -26.96 |
| 2026-09-08 | -26.29 |
| 2026-09-04 | -26.44 |
| 2026-09-03 | -26.89 |
| 2026-09-02 | -26.63 |
| 2026-09-01 | -26.04 |
| 2026-08-31 | -25.87 |
| 2026-08-28 | -26.18 |
| 2026-08-27 | -27.25 |
| 2026-08-26 | -27.50 |
| 2026-08-25 | -27.74 |
| 2026-08-24 | -27.62 |
| 2026-08-21 | -28.02 |
| 2026-08-20 | -27.99 |
| 2026-08-19 | -29.97 |
| 2026-08-18 | -29.19 |
| 2026-08-17 | -29.32 |
| 2026-08-14 | -28.79 |
| 2026-08-13 | -28.74 |
| 2026-08-12 | -29.24 |
| 2026-08-11 | -28.16 |
| 2026-08-10 | -27.71 |
| 2026-08-07 | -28.08 |
| 2026-08-06 | -27.30 |
| 2026-08-05 | -27.78 |
| 2026-08-04 | -24.07 |
| 2026-08-03 | -23.31 |
| 2026-07-31 | -23.11 |
| 2026-07-30 | -24.73 |
| 2026-07-29 | -24.37 |
| 2026-07-28 | -24.61 |
| 2026-07-27 | -24.94 |
| 2026-07-24 | -24.67 |
| 2026-07-23 | -25.54 |
| 2026-07-22 | -25.29 |